The c-myc activation in cervical carcinomas and HPV 16 infections

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 557, Issue 2, 2004, Pages 151-158

  Abba, Martín C ^a   Laguens, Rubén M ^a   Dulout, Fernando N ^a   Golijow, Carlos D ^a  

^a FACULTAD DE CIENCIAS VETERINARIAS   (Argentina)

Author keywords

c myc amplification; Cervical cancer; Human Papillomavirus

Indexed keywords

VIRUS DNA;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE ACTIVATION; GENE AMPLIFICATION; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS STRAIN; VIRUS TYPING; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS;

EID: 0347317996     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2003.10.005     Document Type: Article

References (48)

1. International Agency for Research on Cancer, Monographs on the evaluation of carcinogenic risks to humans: Human Papillomaviruses, vol. 64, Lyon, France, 1995.
2. Bosch F., Manos M., Muñoz N. Prevalence of Human Papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:1995;796-802.
3. zur Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim. Biophys. Acta. 288:1996;55-78.
4. Bosch F., de Sanjosé S. Human Papillomavirus in cervical cancer. Curr. Oncol. Rep. 4:2002;175-183.
5. Nair S.A., Nair N.B., Jayaprakash P.G., Rajalekshmy T.N., Nair M.K., Pillai M.R. ras and c-myc oncoproteins during tumor progression in the uterine cervix. Tumori. 84:1998;583-588.
6. Mourón S.A., Abba M.C., Güerci A., Gómez M.A., Dulout F.N., Golijow C.D. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" HPV types in non-cancerous cervical samples. Mutat. Res. 469:2000;127-134.
7. Golijow C.D., Abba M.C., Mourón S.A., Gómez M.A., Dulout F.N. c-myc gene amplification detected in preinvasive intrepithelial cervical lesion. Int. J. Gynecol. Cancer. 11:2001;462-465.
8. zur Hausen H. Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 9:2000;690-698.
9. Vogelstein B., Kinzler K. The multistep nature of cancer. Trend Genet. 9:1993;138-141.
10. D. Ross, Introduction to Oncogenes and Molecular Cancer Medicine, Springer, New York, 1998.
11. Todd R., Wong D. Oncogenes. Anticancer Res. 19:1999;4729-4746.
12. Colby W.W., Cheng E.Y., Smith D.H., Levinson A.D. Identification and nucleotide sequence of a human locus homologue to the v-myc oncogene of avian myelocytomatosis virus MC 29. Nature. 301:1983;722-725.
13. Koskinen P.J., Alitalo K. Role of myc amplification and overexpression in cell growth, differentiation and death. Semin. Cancer Biol. 4:1993;3-12.
14. Galaktionov K., Chen X., Beach D. Cdc 25 cell-cycle phosphatase as a target of c-myc. Nature. 382:1996;511-517.
15. Facchini L.M., Penn L.Z. The molecular role of myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 12:1998;633-651.
16. Donzelli M., Bernardi R., Negri C., Prosperi E., Padovan L., Lavialle C., Brison O., Scovassi A.I. Apoptosis-prone phenotype of human colon carcinoma cells with a high level amplification of the c-myc gene. Oncogene. 18:1999;439-448.
17. Riou G., Sheng Z.M., Zhou D., Lusinchi A., Le Doussal V., Barrois M. c-myc and c-Ha-ras protooncogenes in cervical cancer: prognostic value. Cancer Bull. 77:1990;341-347.
18. Sivakumari A.N., Madhavan B.N., Puthuveeti G.J., Tayyullathil N.R., Madhavan K.N., Madhavan R.P. Ras and c-myc oncoproteins during tumor progression in the uterine cervix. Tumori. 84:1998;583-588.
19. DePinho R., Schreiber-Agus N., Alt F. myc family oncogenes in the development of normal and neoplatic cells. Adv. Cancer Res. 57:1991;1-46.
20. Brison O. Gene amplification and tumor progression. Biochim. Byophys. Acta. 1155:1993;25-41.
21. Heerdt B.G., Molinas S., Deitch D.D., Augenlicht L.H. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene. 6:1991;125-129.
22. Kreipe H., Feist H.H., Fischer L., Felgner J., Heidorn K., Mettler L., Parwaresch R. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res. 53:1993;1956-1961.
23. Abou-Ellela A., Gramlich T., Fritsch C., Gansler T. C-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod. Pathol. 9:1996;95-98.
24. Jenkins R., Qian J., Lieber M., Bostwick D. Detecton of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57:1997;524-532.
25. Masramon L., Arribas R., Tórtola S., Perucho M., Peinado M.A. Moderate amplifications of c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer. Br. J. Cancer. 99:1998;2349-2356.
26. Christoph F., Schmidt B., Schmidtz-Dräger B.J., Schulz W.A. Over-expression and amplification of the c-myc gene in human urothelial carcinoma. Int. J. Cancer. 84:1999;169-173.
27. Iwasaka T., Yokoyama M., Oh-Uchida M., Matsuo N., Hara K., Fukuyama K., Hachisuga T., Fukuda K., Sugimori H. Detection of Human Papillomavirus genoma and analysis of expression of c-myc and Ha-ras oncogenes in invasive cervical carcinomas. Gynecol. Oncol. 46:1992;298-303.
28. Brewer C., Liao S., Wilczynski S., Pastorekova S., Pastorek J., Zavada J., Kurosaki T., Manetta A., Berman M., DiSaia P., Stanbridge E. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol. Oncol. 63:1996;337-344.
29. Aoyama C., Peters J., Senadheera S., Liu P., Shimada H. Uterine cervical dysplasia and cancer: identification of c-myc status by quantitative polymerase chain reaction. Diag. Mol. Pathol. 7:1998;324-330.
30. Zhang A., Maner S., Betz R., Angstrom T., Stendahl U., Bergman F., Zetterberg A., Wallin K.L. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with Human Papillomavirus infection. Int. J. Cancer. 101:2002;427-433.
31. Gómez M.A., Abba M.C., Golijow C.D. Detección y genotipificación del Papillomavirus Humano (HPV) por PCR-LIS-SSCP. Rev. Arg. Microbiol. 1:2001;22-27.
32. Evander M., Edlund K., Bodun E. Comparison of a one-step and two-step polymerase chain reaction with the degenerate general primers in a population-based study of Human Papillomavirus infection in young Swedish women. J. Clin. Microbiol. 30:1992;987-992.
33. Caballero O.L., Villa L.L., Simpson A.J. Low stringency-PCR (LS-PCR) allows entirely internally standardized DNA quantitation. Nucleic Acids Res. 23:1995;192-193.
34. Tate J.E., Mutter G.L., Prasad C.J., Berkowitz R., Goodman H., Crum C.O. Analysis of HPV-positive and -negative vulvar carcinomas for alterations in c-myc, Ha-, Ki-, and N-ras genes. Gynecol. Oncol. 53:1994;78-83.
35. Kallio P., Syrjänen S., Tervahauta A., Syrjänen K. A simple method for isolation of DNA from formalin-fixed paraffin-embedded samples for PCR. J. Virol. Met. 35:1991;39-47.
36. Couturier J., Sastre-Garau X., Schneider-Maundury S., Labib A., Orth G. Integration of Papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J. Virol. 65:1991;4534-4538.
37. Pillai R. Oncogene expression and prognosis in cervical cancer. Cancer Lett. 5:1991;171-175.
38. Bernard C., Mougin C., Laurent R., Lab M. Oncogene activation: an informative marker for the Human Papillomavirus lesions severity. Cancer Detect. Prev. 18:1994;273-282.
39. zur Hausen H. Immortalization of human cells and their malignant conversion by high risk Human Papillomavirus genotypes. Cancer Biol. 9:1999;405-411.
40. Devictor B., Bonnier P., Piana L., Andrac L., Lavaut M., Allasis C., Charpin C. C-myc protein and Ki-67 antigen immunodetection in patients with uterine cervix neoplasia: a correlation of microcytophotometric analysis and histologic data. Gynecol. Oncol. 49:1993;284-290.
41. Yin X.Y., Grove L., Datta N.S., Long M.W., Prochownik E.V. C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene. 18:1999;1177-1184.
42. Adjei A.A. Blocking oncogenic ras signaling for cancer therapy. J. Nat. Cancer. Inst. 93:2001;1062-1074.
43. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene. 277:2001;1-14.
44. Sastre-Garau X., Favre M., Couturier J., Orth G. Distinct patterns of alteration of myc genes associated with integration of Human Papillomavirus type 16 or type 45 DNA in two genital tumors. J. Gen. Virol. 81:2000;1983-1993.
45. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv. Cancer Res. 55:1990;133-270.
46. Transy C., Forel G., Robinson W.S., Tiollais P., Marion P.L., Buendia M.A. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc. Natl. Acad. Sci. U.S.A. 83:1992;1772-1776.
47. Kersemaekers A.M., Fleuren G.J., Kenter G.G., van den Broek L.J., Uljee S.M., Hermans J., van de Vijver M.J. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 5:1999;577-586.
48. Brenna S.M., Zeferino L.C., Pinto G.A., Souza R.A., Andrade L.A., Vassalo J., Martinez E.Z., Syrjanen K.J. C-myc protein expression is not an independent prognostic predictor in cervical squamous cell carcinoma. Braz. J. Med. Biol. Res. 35:2002;425-430.